What is the current Price Target for the Sonnet BioTherapeutics Holdings Inc stock?

The average Sonnet BioTherapeutics Holdings Inc target price is $240.00. This is 8,502.15% higher than the current stock price. 1 Analyst has issued a Sonnet BioTherapeutics Holdings Inc price target 2025.

How high will the Sonnet BioTherapeutics Holdings Inc stock rise?

No reliable answer can be given as to how high the Sonnet BioTherapeutics Holdings Inc stock will rise. The performance of stocks, including the Sonnet BioTherapeutics Holdings Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Sonnet BioTherapeutics Holdings Inc stock today?

The performance of Sonnet BioTherapeutics Holdings Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Sonnet BioTherapeutics Holdings Inc stock fall?

The decline in Sonnet BioTherapeutics Holdings Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Sonnet BioTherapeutics Holdings Inc Forecast, price target & analysts

$2.66

4.66% today

Nasdaq, Nov 26, 04:44 pm CET

ISIN

US83548R1059

Symbol

SONN

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Sonnet BioTherapeutics Holdings Inc Target price 2024 - Analyst rating & recommendation

Sonnet BioTherapeutics Holdings Inc Classifications & Recommendation:

Buy

100%

Sonnet BioTherapeutics Holdings Inc Price Target

Target Price	$240.00
Price	$2.79
Potential	8,502.15% register free of charge
Number of Estimates	1

	1 Analyst has issued a Sonnet BioTherapeutics Holdings Inc price target 2025. The average Sonnet BioTherapeutics Holdings Inc target price is $240.00. This is 8,502.15% register free of charge higher than the current stock price.
	A rating was issued by 1 analysts: 1 Analysts recommend Sonnet BioTherapeutics Holdings Inc to buy, 0 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Sonnet BioTherapeutics Holdings Inc stock has an average upside potential 2025 of 8,502.15% register free of charge . Most analysts recommend the Sonnet BioTherapeutics Holdings Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 & 2026

Create a premium account to unlock analyst estimates. Learn more

Annually

	Sep '23	2024 Estimates
Earnings Per Share $	-145.12	-26.88
	3.50%	81.48%
P/E		negative

The average Sonnet BioTherapeutics Holdings Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023.

This results in the following potential growth metrics and future valuations:

2023	$-145.12	3.50%
2024	$-26.88 81.48% Unlock

Current	-0.12	500.00%
2024	-0.10 16.67% Unlock

Sonnet BioTherapeutics Holdings Inc...

Discover more stocks with a high price target

Valneva 284.61%

CureVac N.V. 145.33%

Moderna 70.75%

Bavarian Nordic 61.25%

Nel ASA 44.74%

Aixtron 43.84%

Volkswagen VZ 41.85%

Alibaba Group Holding Ltd 40.45%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now